Evidence map›Paper›PMID 38127793›Full record

ArticleAccounts of chemical research2024

Enabling Chemoenzymatic Strategies and Enzymes for Synthesizing Sialyl Glycans and Sialyl Glycoconjugates.

Xi Chen

Open access · hybridAbstract read
In one paragraph

Article in Accounts of chemical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Chemoenzymatic Synthesis of AsymmetricJournal of the American Chemical Society · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Xi ChenDepartment of Chemistry, University of California, Davis, California 95616, United States.ORCID 0000-0002-3160-614X
University of California, Davis · US

Funding

Developing chemoenzymatic strategies, enzymes, and kits for accessible and affordable gangliosidesR44GM139441 · NIGMS · INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. · PI LEE, LIM ANDREW · 2020 to 2022
$2.7M
Affordable sialoglycans and associated reagents for expanded chemoenzymatic productionR42GM143998 · NIGMS · INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. · PI LEE, LIM ANDREW · 2021 to 2024
$2.6M
Engineered probes for sialoglycan detectionR01GM137458 · NIGMS · VANDERBILT UNIVERSITY · PI IVERSON, T M · 2020 to 2023
$1.8M
Glycolipid biointerface to decipher disease-implicated ganglioside-protein interactionsR01GM148803 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI QUAN JASON CHENG · 2023 to 2026
$1.5M
Supplement:Chemoenzymatic construction of synthetic human milk oligosaccharide (HMO) glycomeR01GM148568 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEN, XI · 2022 to 2025
$1.4M
Microbial production of fucosylated human milk oligosaccharidesR01GM145842 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ATSUMI, SHOTA · 2022 to 2025
$1.2M
Chemoenzymatic synthesis of bacterial nonulosonic acids and glycansR01GM141324 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEN, XI · 2021 to 2024
$1.2M
NIGMS NIH HHS R01 GM137458NIGMS NIH HHS R01 GM141324NIGMS NIH HHS R01 GM145842NIGMS NIH HHS R01 GM148568NIGMS NIH HHS R01 GM148803NIGMS NIH HHS R42 GM143998NIGMS NIH HHS R44 GM139441
6 · The paper itself

Abstract

Sialic acids are fascinating negatively charged nine-carbon monosaccharides. Sialic acid-containing glycans and glycoconjugates are structurally diverse, functionally important, and synthetically challenging molecules. We have developed highly efficient chemoenzymatic strategies that combine the power of chemical synthesis and enzyme catalysis to make sialic acids, sialyl glycans, sialyl glycoconjugates, and their derivatives more accessible, enabling the efforts to explore their functions and applications. The Account starts with a brief description of the structural diversity and the functional importance of naturally occurring sialic acids and sialosides. The development of one-pot multienzyme (OPME) chemoenzymatic sialylation strategies is then introduced, highlighting its advantages in synthesizing structurally diverse sialosides with a sialyltransferase donor substrate engineering tactic. With the strategy, systematic access to sialosides containing different sialic acid forms with modifications at C3/4/5/7/8/9, various internal glycans, and diverse sialyl linkages is now possible. Also briefly described is the combination of the OPME sialylation strategy with bacterial sialidases for synthesizing sialidase inhibitors. With the goal of simplifying the product purification process for enzymatic glycosylation reactions, glycosphingolipids that contain a naturally existing hydrophobic tag are attractive targets for chemoenzymatic total synthesis. A user-friendly highly efficient chemoenzymatic strategy is developed which involves three main processes, including chemical synthesis of lactosyl sphingosine as a water-soluble hydrophobic tag-containing intermediate, OPME enzymatic extension of its glycan component with a single C18-cartridge purification of the product, followed by a facile chemical acylation reaction. The strategy allows the introduction of different sialic acid forms and diverse fatty acyl chains into the products. Gram-scale synthesis has been demonstrated. OPME sialylation has also been demonstrated for the chemoenzymatic synthesis of sialyl glycopeptides and

Indexed as

N-Acetylneuraminic AcidSialic AcidsGlycoconjugatesHumansOligosaccharidesSialyltransferasesGlycoconjugatesN-Acetylneuraminic AcidOligosaccharidesSialic AcidsSialyltransferases

Identifiers

PMID38127793
PMCPMC10795189
OpenAlexW4390062786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.